Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "Urine cotinine level" patented technology

Urine cotinine concentrations average four to six times higher than those in blood or saliva, making urine a more sensitive matrix to detect low-concentration exposure. Cotinine levels <10 ng/mL are considered to be consistent with no active smoking.

Method for simultaneously detecting cotinine, phenyl hydroxyacetic acid and phenylglyoxalic acid in human urine based on derivation method

The invention relates to the technical field of biological engineering, in particular to a method for detecting cotinine, mandelic acid and phenylglyoxalic acid in human urine simultaneously on the basis of a derivation method. The method is characterized in that the method comprises: step one, storing collected urine after centrifugal process; step two, taking the urine obtained in step one and adding the urine into internal label benzophenone, diphenylamine, hydrochloric acid and chloroform to carry out extraction through rotating centrifugation, thereby aspirating and recording organic phase as A and taking residual solution for standby; step three, taking the residual solution obtained in step two and adding the residual solution into sodium hydroxide solution and chloroform to carry out secondary extraction through rotating centrifugation, thereby aspirating and recording organic phase as B; step four, mixing the organic phase A extracted in step two and the organic phase B extracted in step three inside a glass tube, and then blowing dry both organic phases; step five, adding acetonitrile into the glass tube adopted in step four for redissolution and adding derivative reagent to carry out derivative reaction; and step six, taking the reaction solution obtained in step five to carry out gas phase chromatography-mass spectrometry combined measurement. The method has the characteristics of simplicity, convenience, quickness, reliable result, high degree of automation and convenient industrialized application.
Owner:陈枢青 +2

Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation

The subject invention concerns materials and methods for treating and / or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and / or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and / or treat Alzheimer's disease, Parkinson's disease, and / or Down's syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant.The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detectable label to a person or animal. The presence of labeled cotinine in neural tissue is then determined. The level and / or location of cotinine can be analyzed and a diagnosis made. The subject invention also concerns cotinine labeled with a detectable label. In one embodiment, the cotinine is labeled with a radioisotope that can be detected by Positron Emission Tomography (PET) or single photon emission computed tomography (SPECT).
Owner:UNIV OF SOUTH FLORIDA +1

High-sensitivity and high-accuracy method for simultaneously determining NNAL and cotinine in urine

The invention discloses a high-sensitivity and high-accuracy method for simultaneously determining NNAL and cotinine in urine. The method comprises the following steps: 1) preparing a single standardstock solution containing the NNAL, the cotinine, isotope-labeled NNAL and isotope-labeled cotinine; 2) preparing mixed standard sample working solutions having a series of concentrations and containing the NNAL and the cotinine, and making a standard curve; 3) taking a to-be-determined urine sample, adding a phosphate buffer solution containing an isotope-labeled internal standard, and adding 15-25 [mu]L of beta-glucuronidase for enzymolysis; and 4) taking out the sample solution subjected to the enzymolysis, naturally cooling the sample solution into the room temperature, performing solid-phase extraction, performing instrument analysis, and performing calculation according to the standard curve made in the step 2) to obtain the content of the NNAL and the cotinine. The method effectively solves the problems of complex pretreatment and long consumed time of an existing method for simultaneously testing the NNAL and the cotinine in the urine; and meanwhile, the matrix effect in the urine is greatly reduced, so that the detection sensitivity and accuracy are improved.
Owner:SICHUAN UNIV

Method for rapidly detecting content of nicotine and cotinine in meconium of newborn

The invention discloses a method for rapidly detecting the content of nicotine and cotinine in meconium of a newborn. The method comprises the steps: extracting a meconium sample of the newborn by using a medical cotton swab; dropwise adding an isotopic internal standard methanol solution containing the nicotine and cotinine to a part, away from the sample by 0.5mm to 1.5mm, on the medical cotton swab as an extracting ionization reagent, so as to ionize the sample and generate atomization, and enabling a mass-spectrum centerline to be parallel to a toothpick at the distance of 0.5cm to 5cm; starting up a mass spectroscopy system, and setting as a cation mode. The method disclosed by the invention has the advantages that a pretreatment process for the sample is simplified, sample pretreatment such as extraction and chromatographic separation is not carried out, and the newborn is subjected to direct ionization mass spectroscopy through swabbing an electrospray mass spectrum by adopting the medical cotton swab, so that the whole analysis process is greatly simplified; the medical cotton swab is clean and hygienic and is particularly applicable to clinical large-batch analysis. Sample pretreatment steps are simplified, and direct ionization is carried out, so that the correctness and accuracy of assaying are greatly improved.
Owner:江西省妇幼保健院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products